



The fluctuation of BRCA1 gene is associated in pathogenesis of familial colorectal cancer type X

Colorectal cancer

Mahdieh Nejadtaghi¹, Effat Farrokhi¹, Ali Akbar Samadani², Mehrdad Zeinalian³, Morteza Hashemzadeh-Chaleshtori¹

¹Cellular and Molecular Research Center, Shahrekord University of Medical Science, Shahrekord,

²Faculty of Medicine, Research center of Physiology, Cancer Research Center, Semnan University of Medical Sciences, Semnan,

³Department of Genetics & Molecular biology, School of Medicine Isfahan University of Medical Sciences, Isfahan, Iran

Abstract

Aim: Among families fulfilling the Amsterdam criteria HNPCC, nearly 40 % of this cases are microsatellite stable and not DNA mismatch repair gene (MMR) and also these mutations were found in this situation. Correspondingly, these families were nominated as familial colorectal cancer type X (FCCTX). The BRCA1 gene plays a role in main cellular pathways and germ line mutations in this gene could underlie different familial cancers. **Material and Method:** In this way, samples were selected according to previous study that patients who met Amsterdam criteria for lynch syndrome but did not have defective MMR gene and are known as FCCTX. So, 25 normal tissues have been considered for further studies and HRM method was used in order to detect mutations in 2, 3,5,16 and 20 exons of the BRCA1 gene. **Results:** For all samples, the DNA was tested by HRM for the detection of mutations in BRCA1 exons. After normalization and temperature shifting, a clear difference was evident between the melt curves for each sample. Through the different samples of each group, one was selected for sequencing. Based on our sequencing results deleterious BRCA1 gene mutations were not identified and there was no significant difference between the sequences of the samples with a different melting curve. **Discussion:** Conclusively, our study showed that although BRCA1 is a critical gene playing role in several CRCs, it maybe plays an insignificant role in this type of CRC.

Keywords

FCCTX; HNPCC; Lynch Syndrome; BRCA1; HRM

DOI: 10.4328/JCAM.5530

Received: 24.11.2017 Accepted: 24.11.2017 Printed: 01.05.2017

J Clin Anal Med 2017;8(suppl 5): 496-9

Corresponding Author: Effat Farrokhi, Cellular and Molecular Research Center, Shahrekord University of Medical Science, Shahrekord, Iran. Postal code: 8814683991

T.: +98 38 33346692 F.: +98 38 33330709 E-Mail: e_farrokhi_k@yahoo.com

Introduction

Colorectal cancer (CRC) is the third most common cancer in males and second most common cancer in females worldwide [1]. Inherited elements have a critical role in at least one third of all CRCs [2]. Hereditary nonpolyposis colorectal cancer (HNPCC) is one of the most common inherited CRC syndromes, due to mutations in a DNA mismatch repair gene [3,4].

Among families fulfilling the Amsterdam criteria HNPCC, nearly 40 % of them are microsatellite stable and not DNA mismatch repair gene (MMR) mutations were found among them. These families were nominated as familial colorectal cancer type X (FCCTX) [5]. Individuals with FCCTX display diminished risk for extracolonic neoplasms, and tumorigenesis process tends to occur later in life [6,7]. An ambiguity in the nature of the disease for FCCTX presents considerable challenges in terms of deciding upon the best approach to interrogate its genetic basis [8].

The *BRCA1* gene plays a role in numerous main cellular pathways, including checkpoint activation, DNA damage repair, and chromatin remodeling. It seems that the *BRCA1* tumor suppression function is related to its function in homologous recombination damage repair [9].

Germline mutations in this gene could underlie different familial cancers [8], for example in addition to breast and ovarian cancer its role in prostate, pancreatic and stomach cancers was seen [10]. A recent prospective study of 7015 women with *BRCA1* mutation recognized fivefold increased risk of colorectal cancer among *BRCA1* mutation carriers younger than 50 years [11].

In this study, in order to identify new mutations in genes involved in FCCTX, we focus on *BRCA1* gene.

In the present study, we have analyzed mutations in some hot spot exons of the *BRCA1* gene by High Resolution Melting (HRM) technique. HRM consists of the accurate checking the alteration in fluorescence caused by the release of an intercalating DNA dye from a DNA duplex as it is denatured by increasing temperature [12]. This technique has been developed recently and displays great potential for scanning germline and somatic mutations [13].

Material and Method

Sample collection and preparation

The Samples were collected from Poursina Hakim Research Center, a referral gastroenterology clinic in central part of Iran, Isfahan. Samples were selected according to previous study that patients who met Amsterdam criteria for lynch syndrome but did not have defective MMR gene [14]. Out of 219 patients who were under 50 years at diagnosis, 45 HNPCC families were selected meeting AC-1 for lynch syndrome. From those, 25 families that did not have defective MMR gene and were known as colorectal cancer type X were selected. The normal tissues of these patients have been considered for further studies. 10µm thickness sections were prepared from 25 samples using microtome.

Mutation screening by HRM

DNA extraction was performed using DNA FFPE Tissue Kit (Qiagen, Hilden, Germany), according to the manufacturer's proto-

col. DNA concentration and purity were measured by UV spectrophotometry using Nanodrop 2000 (Thermo Fisher Scientific, Waltham, MA, USA).

In this study, we used HRM method to detect mutations in some exons of the *BRCA1* gene. We investigated five *BRCA1* hot spot exons included 2, 3, 5, 16 and 20 exons.

Designing primer for HRM needs certain special attention for instance, because DNA derived from FFPE is often degraded. Primers were designed by beacon designer software. Primer sequences and amplicon size are given in table 1.

PCR conditions and HRM assay

PCR and HRM analysis was performed in 0.1ml tubes on the Rotor-Gene 6000 (Corbett Research, Sydney, Australia). All samples were tested in duplicate and one negative DNA control was included in each experiment. 10 ng of DNA was amplified in a final volume of 10 µl containing Type-it HRM PCR Kit (Qiagen, Hilden, Germany), forward primer, reverse primer and nuclease free H₂O.

PCR cycling parameters were according to the following conditions: initial denaturation at 95°C for 5 min; 45 cycles of 95°C for 15 seconds, 60°C for 25 seconds and 72°C for 25 seconds. The final melting program was melting from 70°C to 90°C, with a ramp of 0.2°C per second. The cycling and melting conditions for all exons were the same.

These experiments have been done on all of 25 normal tissues. Results were analyzed as fluorescence versus temperature graphs by accompanying Gene Scanning software (v1.7). With normalized, temperature-shifted melting curves displayed as difference plot. Those samples showed a different melting curve were sequenced.

Ethical approval

This study was conducted on samples utilized in previous study and ethical approval process has been already explained in the

Table 1. Primer sequences for HRM

Exon	Primer sequence	Amplicon size
2	F: GTGTAAAGTTCATTGGAACAGAAAG R: CATAGGAGATAATCATAGGAATCCCA	162
3	F: AGTCATAACAGCTCAAAGTTGAAC R: TGGAGCCACATAACACATTCA	187
5	F: TTCATGGCTATTTGCCTTTTGAG R: TGCTTCCAACCTAGCATCATTAC	193
16-1	F: ATAAACTTCTCCATTCTTTTCAG R: TATGAGCAGCAGCTGGACTC	205
16-2	F: GCTGCTGCTCATACTACTG R: TCCAGAAATGTTAAGTCTTAGT	198
20	F: TCCTGATGGGTTGTGTTTGG R: TGGTGGGGTGAGATTTTTGTC	157




Figure 1. Melting curve and Normalized HRM difference graph of exon 2

previous study [22]. Ethical approval was received from the Medical ethics committee of Shahrekord University of Medical Sciences (Research project Number: 91-01-70-1364) and informed consent was obtained.

Result

The DNA extracted from normal tissues of 25 FCCTX samples were tested by HRM for the detection of mutations in some exons of *BRCA1* gene. After normalization and temperature shifting, a clear difference was evident between the melt curves for each exon. The samples that showed a different melting curve in comparison to others, were categorized in different groups. Then through the different samples of each group, one sample was selected for sequencing.

Based on our sequencing results deleterious *BRCA1* gene mutations were not identified. There was no significant difference between the sequences of the samples with a different melting curve. The result of one of the investigated exons (exon2) was shown in figure 1. The results of other exons were similar (data not shown). Other information available.

Discussion

Since the genetic etiology for FCCTX is largely unknown, genetic confirmation of the diagnosis can help direct surveillance recommendations for the patient and their at-risk family members [15].

BRCA1 gene has high tumor heterogeneity and the role of its mutations in numerous cancers specially in CRCs is a probable event [16,17].

For our purpose HRM has been used as a rapid screen for identifying *BRCA1* mutations, finally, after comparing melting curves and analyzing sequencing results, our study showed that there is not any association between the *BRCA1* exons 2, 3, 5, 16 and 20 mutations and FCCTX. This finding is in contrast to same studies which done about the role of *BRCA1* mutations in other CRCs.

For example, in a study by Phelan C et al 7015 women with a *BRCA1* mutation were followed in order to detect new cases of colorectal cancer. They showed that twenty-one incident colorectal cancer cases were discovered among all mutation carriers and there was a substantial fivefold increased risk of colorectal cancer among *BRCA1* mutation carriers younger than 50 years [18]. Also in the studies done in the Breast Cancer Linkage Consortium the authors reported modest but significant increases in colorectal cancer risk in family members of families with a *BRCA1* or a *BRCA2* mutation. The relative risk associated with a *BRCA1* mutation was 2.03 [19,20].

There are also some studies, showing a probable role for *BRCA1* in colon cancer in the animal models, for example, it has been shown that mice deficient in *BRCA1* will be affected by a varied range of carcinomas, frequently breast and lung but also gastric, endometrial and colon cancer [21].

In the investigated exons we did not find any mutation in FCCTX patients. It can be due to the limited number of samples. Our samples obtained from the screening of 219 CRC patients and only 25 samples remained, which represents FCCTX. On the other hand the mutations in other exons of the *BRCA1* gene may be involved in causing disease. We investigated hot spot exons and

it is recommended to check other exons. Finally, although *BRCA1* is a critical gene playing role in several CRCs, it maybe plays an insignificant role in this type of CRC and other studies confirm this subject [22]. There has not been strong evidence that colon cancer is part of the *BRCA1* phenotype. Although further studies are needed with a higher confirmation rate of colon cancers.

One of the most notable aspects of our study is that, this is the first time that the role of *BRCA1* mutations has been analyzed in this type of colorectal cancer and suggest that other *BRCA1* exons investigate.

Acknowledgments

This data has been obtained from a MSc. thesis. Hereby, we gratefully thank Deputy of Research and Technology of Shahrekord University of Medical Science, Shahrekord, Iran.

Competing interests

The authors declare that they have no competing interests.

References

- Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. *CA: a cancer journal for clinicians* 2011;61(2):69-90.
- Lichtenstein P, Holm NV, Verkasalo PK, Iliadou A, Kaprio J, Koskenvuo M et al. Environmental and heritable factors in the causation of cancer—analyses of cohorts of twins from Sweden, Denmark, and Finland. *New England journal of medicine* 2000;343(2):78-85.
- Kaz AM, Brentnall TA. Genetic testing for colon cancer. *Nat Clin Pract Gastroenterol Hepatol* 2006;3(12):670-9.
- Sieber OM, Lipton L, Crabtree M, Heinemann K, Fidalgo P, Phillips RK et al. Multiple colorectal adenomas, classic adenomatous polyposis, and germ-line mutations in MYH. *New England journal of medicine* 2003;348(9):791-9.
- Abdel-Rahman WM, Peltomaki P. Lynch syndrome and related familial colorectal cancers. *Critical Reviews™ in Oncogenesis* 2008;14(1)
- Lindor NM, Rabe K, Petersen GM, Haile R, Casey G, Baron J et al. Lower cancer incidence in Amsterdam-I criteria families without mismatch repair deficiency: familial colorectal cancer type X. *Jama* 2005;293(16):1979-85.
- Engel C, Loeffler M, Steinke V, Rahner N, Holinski-Feder E, Dietmaier W et al. Risks of less common cancers in proven mutation carriers with lynch syndrome. *Journal of Clinical Oncology* 2012;30(35):4409-15.
- Ku C-S, Cooper DN, Wu M, Roukos DH, Pawitan Y, Soong R et al. Gene discovery in familial cancer syndromes by exome sequencing: prospects for the elucidation of familial colorectal cancer type X. *Modern Pathology* 2012;25(8):1055-68.
- Caestecker KW, Van de Walle GR. The role of *BRCA1* in DNA double-strand repair: past and present. *Experimental cell research* 2013;319(5):575-87.
- Cavanagh H, Rogers KM. The role of *BRCA1* and *BRCA2* mutations in prostate, pancreatic and stomach cancers. *Hereditary cancer in clinical practice* 2015;13(1):1.
- Sopik V, Phelan C, Cybulski C, Narod S. *BRCA1* and *BRCA2* mutations and the risk for colorectal cancer. *Clinical genetics* 2015;87(5):411-8.
- Wittwer CT, Reed GH, Gundry CN, Vandersteen JG, Pryor RJ. High-resolution genotyping by amplicon melting analysis using LCGreen. *Clinical chemistry* 2003;49(6):853-60.
- Taylor CF. Mutation scanning using high-resolution melting. *Biochemical Society Transactions* 2009;37(2):433-7.
- Zeinalian M, Hashemzadeh-Chaleshtori M, Salehi R, Kazemi M, Emami MH. Tumor microsatellite instability and clinicopathologic features in Iranian colorectal cancer patients at risk for Lynch syndrome. *Journal of research in medical sciences: the official journal of Isfahan University of Medical Sciences* 2015;20(2):154.
- Carethers JM, Stoffel EM. Lynch syndrome and Lynch syndrome mimics: The growing complex landscape of hereditary colon cancer. *World journal of gastroenterology: WJG* 2015;21(31):9253.
- Wyman C, Ristic D, Kanaar R. Homologous recombination-mediated double-strand break repair. *DNA repair* 2004;3(8):827-33.
- Gudmundsdottir K, Ashworth A. The roles of *BRCA1* and *BRCA2* and associated proteins in the maintenance of genomic stability. *Oncogene* 2006;25(43):5864-74.
- Phelan C, Iqbal J, Lynch H, Lubinski J, Gronwald J, Moller P et al. Incidence of colorectal cancer in *BRCA1* and *BRCA2* mutation carriers: results from a follow-up study. *British journal of cancer* 2014;110(2):530-4.
- Thompson D, Easton D, Consortium BCL. Variation in cancer risks, by mutation position, in *BRCA2* mutation carriers. *The American Journal of Human Genetics* 2001;68(2):410-9.
- Ford D, Easton D, Stratton M, Narod S, Goldgar D, Devilee P et al. Genetic heterogeneity and penetrance analysis of the *BRCA1* and *BRCA2* genes in breast cancer families. *The American Journal of Human Genetics* 1998;62(3):676-89.

21. Moynahan ME. The cancer connection: BRCA1 and BRCA2 tumor suppression in mice and humans. *Oncogene* 2002;21(58)
22. Ford D, Easton DF, Bishop DT, Narod SA, Goldgar DE. Risks of cancer in BRCA1-mutation carriers. *The Lancet* 1994;343(8899):692-5.

How to cite this article:

Nejadtaghi M, Farrokhi E, Samadani AA, Zeinalian M, Hashemzadeh-Chaleshtori M. The fluctuation of BRCA1 gene is associated in pathogenesis of familial colorectal cancer type X. *J Clin Anal Med* 2017;8(suppl 5): 496-9.